Study Description: TrialNet is an international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes. TrialNet was established in response to the Surgeon General's Report Healthy People 2000. This report identified diabetes as a national health objective for the Nation. In response to the report, Congress created the Diabetes Research Working Group (DRWG) to develop a plan for diabetes research. One recommendation of the DRWG was to conduct additional research studies (clinical trials) to prevent type 1 diabetes. The TrialNet Natural History Study is divided into two parts or phases: Screening and Monitoring. Screening involves drawing blood and shipping the specimen to a core laboratory for assessments of autoantibodies that are predictive of the development of type 1 diabetes (T1D). Those who test positive are eligible to enter the monitoring phase which includes a baseline monitoring visit at a TrialNet site to estimate the level of risk of developing T1D. Participants are followed-up either annually or semi-annually depending on their risk level. All participants in the monitoring phase will have repeat testing for autoantibodies and HbA1c; those in the higher risk will be closely monitored with Oral Glucose Tolerance Tests (OGTT). Participants who initially receive annual monitoring will be followed with semi-annual monitoring if their risk level for developing T1D increases
Principal Investigator: Jin-Xiong She
Eligibility Criteria: 1. Be willing to give informed consent for the screening procedure. 2. Be aged 1- 45 years (children less than one year of age will not be screened). 3. Have a blood relative with T1D: primarily first degree relatives (siblings, offspring, and parents), but individuals aged 20 years or less who have second or third degree relatives (nieces, nephews, aunts, uncles, grandparents, cousins, half siblings) with T1D will also be eligible. In general, a proband is an individual with onset of diabetes before age 40 years and prescription of insulin therapy within one year of diagnosis. Those who are considered to have T1D but do not meet this definition will be referred for decision regarding eligibility to the TrialNet Eligibility and Events Committee.
Compensation: Yes, subjects will be compensated.
Compensation Explanation: Upon completion of every study visit in Monitoring, 1-2 visit per year, subject will receive a payment of $50 through the GreenPhire ClinCard system, as outlined in Monitoring ICD.
If you don't see specific studies that interest you, please submit your contact information for future studies.